BioXcel Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.31
- Today's High:
- $3.52
- Open Price:
- $3.52
- 52W Low:
- $8.795
- 52W High:
- $34.125
- Prev. Close:
- $3.51
- Volume:
- 765544
Company Statistics
- Market Cap.:
- $566.57 million
- Book Value:
- 1.821
- Revenue TTM:
- $581000
- Operating Margin TTM:
- -30871.43%
- Gross Profit TTM:
- $355000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -57.32%
- Return on Equity TTM:
- -151.47%
Company Profile
BioXcel Therapeutics Inc had its IPO on 2018-03-08 under the ticker symbol BTAI.
The company operates in the Healthcare sector and Biotechnology industry. BioXcel Therapeutics Inc has a staff strength of 183 employees.
Stock update
Shares of BioXcel Therapeutics Inc opened at $3.52 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.31 - $3.52, and closed at $3.34.
This is a -4.84% slip from the previous day's closing price.
A total volume of 765,544 shares were traded at the close of the day’s session.
In the last one week, shares of BioXcel Therapeutics Inc have slipped by -12.79%.
BioXcel Therapeutics Inc's Key Ratios
BioXcel Therapeutics Inc has a market cap of $566.57 million, indicating a price to book ratio of 3.9656 and a price to sales ratio of 4131.888.
In the last 12-months BioXcel Therapeutics Inc’s revenue was $581000 with a gross profit of $355000 and an EBITDA of $-179032992. The EBITDA ratio measures BioXcel Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BioXcel Therapeutics Inc’s operating margin was -30871.43% while its return on assets stood at -57.32% with a return of equity of -151.47%.
In Q1, BioXcel Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
BioXcel Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-6.64 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BioXcel Therapeutics Inc’s profitability.
BioXcel Therapeutics Inc stock is trading at a EV to sales ratio of 2657.9442 and a EV to EBITDA ratio of -2.7479. Its price to sales ratio in the trailing 12-months stood at 4131.888.
BioXcel Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $180.10 million
- Total Liabilities
- $28.76 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
BioXcel Therapeutics Inc ended 2024 with $180.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $180.10 million while shareholder equity stood at $53.01 million.
BioXcel Therapeutics Inc ended 2024 with $2.57 million in deferred long-term liabilities, $28.76 million in other current liabilities, 29000.00 in common stock, $-464341000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $165.52 million and cash and short-term investments were $165.52 million. The company’s total short-term debt was $325,000 while long-term debt stood at $95.06 million.
BioXcel Therapeutics Inc’s total current assets stands at $177.27 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $283000.00 compared to accounts payable of $7.74 million and inventory worth $1.95 million.
In 2024, BioXcel Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, BioXcel Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.34
- 52-Week High
- $34.125
- 52-Week Low
- $8.795
- Analyst Target Price
- $53
BioXcel Therapeutics Inc stock is currently trading at $3.34 per share. It touched a 52-week high of $34.125 and a 52-week low of $34.125. Analysts tracking the stock have a 12-month average target price of $53.
Its 50-day moving average was $7.19 and 200-day moving average was $18.98 The short ratio stood at 7.5 indicating a short percent outstanding of 0%.
Around 3126.4% of the company’s stock are held by insiders while 5355.6% are held by institutions.
Frequently Asked Questions About BioXcel Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer’s disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.